Markets:

Overview

News

Currencies

International

Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

114.39 +0.10 (+0.09%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement ↗

March 02, 2026

Arcellx shares have jumped 75% in 2026, but that's because the stock will soon be off the market.

Via The Motley Fool

Topics Regulatory Compliance

Arcellx President Sells $10M Worth of Shares After Acquisition Announcement ↗

March 02, 2026

Arcellx shares have jumped 75% in 2026, but that's because the stock will soon be off the market.

Via The Motley Fool

Topics Regulatory Compliance

Let's take a look at the stocks that are in motion in today's session. ↗

February 23, 2026

Via Chartmill

Here are the top movers in Monday's session. ↗

February 23, 2026

Via Chartmill

4 Analysts Assess Arcellx: What You Need To Know ↗

July 31, 2025

Via Benzinga

(ACLX) - Analyzing Arcellx's Short Interest ↗

January 14, 2025

Via Benzinga

These stocks are gapping in today's session ↗

February 23, 2026

Via Chartmill

These stocks are moving in today's pre-market session ↗

February 23, 2026

Via Chartmill

Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗

February 23, 2026

Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal.

Via Stocktwits

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗

February 22, 2026

Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.

Via The Motley Fool

Topics Regulatory Compliance

In-Depth Examination Of 14 Analyst Recommendations For Arcellx ↗

December 09, 2024

Via Benzinga

14 Analysts Have This To Say About Arcellx ↗

December 09, 2024

Via Benzinga

Analyst Expectations For Arcellx's Future ↗

November 08, 2024

Via Benzinga

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.

Via The Motley Fool

Topics Regulatory Compliance

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

February 10, 2026

Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the...

Via Finterra

Topics Economy Intellectual Property

Arcellx Director Sells 6,000 Shares for $450,000 ↗

January 31, 2026

A director at one of the top clinical-stage biotech companies sold 6,000 insider shares towards the end of January 2026 amid the company's stock having an underwhelming performance in 2025.

Via The Motley Fool

Topics Regulatory Compliance

Navigating 7 Analyst Ratings For Arcellx ↗

November 06, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Arcellx ↗

October 22, 2024

Via Benzinga

The Small-Cap M&A Boom of 2026: How $440 Billion in Dry Powder and Rate Cuts Are Remaking the Market

January 27, 2026

As of January 27, 2026, the financial landscape has undergone a dramatic transformation. After a prolonged "deal winter" that chilled the markets through 2023 and much of 2024, the small-cap sector is...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Which stocks are experiencing notable movement on Monday? ↗

November 24, 2025

Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Arcellx (ACLX) Q2 Revenue Drops 72% ↗

August 07, 2025

Via The Motley Fool

FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers ↗

June 30, 2025

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.

Via Benzinga

The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗

June 20, 2025

Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.

Via Investor's Business Daily

Topics Government

Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday ↗

May 21, 2025

Via Benzinga

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday ↗

April 02, 2025

Via Benzinga

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention ↗

February 12, 2025

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

Via Benzinga

Arcellx Stock Earns 82 Relative Strength Rating ↗

December 27, 2024

Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.

Via Investor's Business Daily

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. ↗

December 09, 2024

The companies held competing events on Sunday to discuss their multiple myeloma treatments.

Via Investor's Business Daily

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients ↗

December 09, 2024

Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes.

Via Benzinga

Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

November 06, 2024

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.